Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMD Serono, an affiliate of Merck, and Fast Forward, a subsidiary of the National Multiple Sclerosis Society, have joined to develop therapies for nervous system damage in multiple sclerosis (MS).
Subscribe to our email newsletter
This is the fourth ‘Request for Proposals’ (RFP) issued through the multi-year collaboration between Fast Forward and Merck KGaA to drive the commercial development of MS therapies.
Fast Forward will provide resources for underfunded academic institutions and seed-to-early-stage companies engaged in research concerning multiple sclerosis.
EMD Serono US Research vice president Steve Arkinstall said through the partnership the company hopes to expand its knowledge and understanding of MS to make new treatment options for people suffering with the disease.